Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021
Shots:
- The P-IIb LTS part A assesses tolebrutinib (5/15/30/60mg/day) in patients with RMS and in Part B- where all participants switched to the 60mg
- The study demonstrated a reduction in MS disease activity as MRI and showed a favorable 1yrs. tolerability. "Mean EDSS scores across treatment groups ranged from 2.18 to 2.65 at baseline and remained relatively stable over 48 weeks. For the 60/60mg treatment group- mean (SD) score was 2.65 (1.22) at baseline and 2.45 (1.31) at Week 48; low MRI lesion activity in patients who started on or switched to 60mg. 98% of patients remained on treatment in P-IIb extension study @48wks.
- @48wks. of the extension study- low Gd-enhancing lesions (<0.4) in the 60/60mg arm. Additionally- data from in vitro studies in human microglia extended previous observations that BTK-dependent inflammatory signaling can be modulated by tolebrutinib
Ref: Globe Newswire | Image: Medcity News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com